TPCera ^{For Profit}

TPCera develops a new type of immunomodulatory compound that shifts the immune system from an inflammatory state into an anti-inflammatory one. TPCera's lead compound is TPC1022. The company is focused on shifting macrophages from M1 to M2, which has the potential to modulate autoimmune diseases.